Amniotics AB (publ) Announces Resignation of Board Member
12 oktober, 2021
Amniotics announces the resignation of Lars Stigsson from the Board of Directors of Amniotics.
Lars Stigsson, a member of the Board of Directors of Amniotics AB (publ) has announced his resignation from the Board of Directors of the company on 12 October 2021. Mr. Stigsson has served on the Board since 2019 and has decided to resign due to personal reasons.
– On behalf of Amniotics and the entire Board I would like to sincerely thank Lars for his great contributions and commitment. Lars knowledge and insights in patents have been very valuable to the Board, says Amniotics Chairman Peter Buhl Jensen.
The process of electing a board member to replace Mr. Stigsson will follow due process.
About Amniotics
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University HospitalUniversity Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics has itsit´s headquarter in Lund, Sweden.
Amniotics (publ) has it´s headquarter in Lund, Sweden.
Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.
The company is listed at Nasdaq First North Growth Market in Stockholm.
Learn more at www.amniotics.com.
Attachments
Amniotics AB (publ) Announces Resignation of Board Member
Ämnen i artikeln
Amniotics AB (publ) Announces Resignation of Board Member
12 oktober, 2021
Amniotics announces the resignation of Lars Stigsson from the Board of Directors of Amniotics.
Lars Stigsson, a member of the Board of Directors of Amniotics AB (publ) has announced his resignation from the Board of Directors of the company on 12 October 2021. Mr. Stigsson has served on the Board since 2019 and has decided to resign due to personal reasons.
– On behalf of Amniotics and the entire Board I would like to sincerely thank Lars for his great contributions and commitment. Lars knowledge and insights in patents have been very valuable to the Board, says Amniotics Chairman Peter Buhl Jensen.
The process of electing a board member to replace Mr. Stigsson will follow due process.
About Amniotics
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University HospitalUniversity Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics has itsit´s headquarter in Lund, Sweden.
Amniotics (publ) has it´s headquarter in Lund, Sweden.
Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.
The company is listed at Nasdaq First North Growth Market in Stockholm.
Learn more at www.amniotics.com.
Attachments
Amniotics AB (publ) Announces Resignation of Board Member
Ämnen i artikeln
Rapportperioden
Plejd
Inflationen
-992x558.webp&w=3840&q=75)
Rapportperioden
Plejd
Inflationen
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
